Provided by Tiger Trade Technology Pte. Ltd.

ANI Pharmaceuticals

71.92
-1.3300-1.82%
Post-market: 71.920.00000.00%19:30 EDT
Volume:580.54K
Turnover:42.01M
Market Cap:1.65B
PE:15.84
High:74.99
Open:73.54
Low:71.56
Close:73.25
52wk High:99.50
52wk Low:70.15
Shares:22.97M
Float Shares:20.28M
Volume Ratio:1.29
T/O Rate:2.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.54
EPS(LYR):3.32
ROE:20.46%
ROA:5.45%
PB:2.77
PE(LYR):21.66

Loading ...

ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules

THOMSON REUTERS
·
Apr 13

Is ANI Pharmaceuticals (ANIP) Attractive Around US$80 After Recent Share Price Gains?

Simply Wall St.
·
Apr 11

ANI Pharmaceuticals announces annual shareholder meeting

Reuters
·
Apr 10

BUZZ-U.S. STOCKS ON THE MOVE-Delta, GATX, Humana

Reuters
·
Apr 08

BUZZ-ANI Pharmaceuticals jumps after launching generic heart drug

Reuters
·
Apr 08

ANI Pharmaceuticals Says US FDA Approves Isosorbide Mononitrate Tablet

MT Newswires Live
·
Apr 08

ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet

THOMSON REUTERS
·
Apr 08

ANI Pharmaceuticals replaces EisnerAmper with Ernst & Young as auditor

Reuters
·
Apr 08

ANI publishes Phase 4 NEW DAY ILUVIEN DME trial results in Ophthalmology journal

Reuters
·
Apr 07

ANI Pharmaceuticals Announces Publication of New Day Clinical Trial Results in Ophthalmology

THOMSON REUTERS
·
Apr 07

ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology

GlobeNewswire
·
Apr 07

ANI Pharmaceuticals (ANIP) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Mar 25

Barclays Keeps Their Buy Rating on ANI Pharmaceuticals (ANIP)

TIPRANKS
·
Mar 19

Is ANI Pharmaceuticals (ANIP) Pullback Hiding A Contradiction In Its Valuation Story

Simply Wall St.
·
Mar 18

ANI Pharmaceuticals Head of Rare Disease Christopher Mutz Disposes of Common Shares

Reuters
·
Mar 14

ANI Pharmaceuticals Sr. VP, General Counsel and Secretary Meredith Cook Disposes of Common Shares

Reuters
·
Mar 14